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between projected costs across methods was statistically
signiﬁcant (Kappa > 0.80, p < 0.001) in each head-to-
head comparison, conﬁrming the feasibility of using the
LR to approximate the results of the decision analysis.
CONCLUSIONS: Both methods demonstrate that glip-
izide GITS is the least expensive ﬁrst-line therapy for
newly diagnosed Type-2 diabetes patients, followed by
metformin and rosiglitazone. The LR can be used as a
quick and easy tool for use in approximation of the more
comprehensive decision tree.
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OBJECTIVE: The goal of this study was to compare
resource utilization for two insulin delivery devices:
InnoLet® and vial/syringe. METHODS: Diabetic patients
requiring assistance with insulin injections (vision and/
or motor impairments) were followed over two 6-week
periods in a randomized crossover study to estimate the
resource utilization associated with different insulin deliv-
ery systems: the InnoLet® insulin doser or the vial and
syringe. A total of 79 patients were enrolled in the study.
Resource utilization was measured as the number of visits
per day which the nurse/caregivers needed to have with
the patient in order to assist (if required) with an injec-
tion, times the costs for such a visit ($80/hour; minimum
visit 1 hour based on local visiting nursing rate) plus the
daily cost for insulin. RESULTS: The mean age of patients
was 68.2 ± 8.6 years, with a mean A1c level of 7.5 ± 1.4
at baseline. Patients were previously treated with
vial/syringe and required assistance with making injec-
tions. Reported major hypoglycemic events occurred as
frequently with both treatments. The mean daily costs for
home visits associated with the injections were $99 and
$179 for the InnoLet and vials/syringe patients, respec-
tively (p < 0.001). Fifty-three percent of the patients
became independent of nursing/caregiver assistance for
the injections when using InnoLet®. Furthermore, the
mean time spent by nurses or caregivers for assisting in
injection preparation was lower for patients using the
InnoLet doser than for the vial and syringe. CONCLU-
SIONS: Patients using the InnoLet® doser required sig-
niﬁcantly fewer visits from nurses/caregivers, resulting in
less resource utilization, and use of InnoLet® fostered
independence in patients who had difﬁculty with self-
injection using vial and syringe.
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Becaplermin (Regranex®), a recombinant human
platelet-derived growth factor, and graftskin (Apligraf®),
a bilayered tissue-engineered human skin equivalent,
promote the local wound healing process and therefore
reduce the time to complete healing and rate of amputa-
tion of lower extremity in diabetic foot ulcer patients.
However, very limited information is available for the rel-
ative cost-effectiveness of these new treatments. OBJEC-
TIVES: To evaluate the cost-effectiveness of graftskin plus
standard foot care and becaplermin plus standard foot
care in comparison to the standard foot care alone from
the societal perspective. METHODS: A decision analysis
model was built for chronic diabetic foot ulcer patients.
Study period was one year. The effectiveness was mea-
sured in quality-adjusted-life years (QALYs). Data for
QALYs, transition probabilities, efﬁcacy, and costs were
taken mostly from the literature. All costs were adjusted
to 2002 US dollars. Sensitivity analyses were performed
on important parameters including costs and efﬁcacy 
of graftskin and becaplermin, and costs of amputation.
RESULTS: In the base case analysis, graftskin was a dom-
inant strategy over becaplermin and standard care. Also,
becaplermin was the dominant strategy over standard
care alone. Compared to the standard care group and the
becaplermin group, the graftskin group had higher
QALYs (difference was 0.03 and 0.06, respectively). In
terms of savings of medical costs, the graftskin group
gained $2202 and $179, compared to the standard care
group and the becaplermin group during the study
period. The results of the sensitivity analysis were con-
sistent with the results of the base case analysis. CON-
CLUSIONS: Although the standard care costs less at the
initial state, patients receiving the standard care only are
more likely to have costly outcomes compared to patients
receiving graftskin or becaplermin, and this translates
into higher expected costs. Also, results indicate that
treating diabetic foot ulcer patients with graftskin was
more cost-effective than treating with becaplermin.
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